Leerink Partners Resumes Acorda Therapeutics, Inc. (ACOR) at Market Perform

October 4, 2016 6:28 AM EDT
Get Alerts ACOR Hot Sheet
Price: $19.70 -1.99%

Rating Summary:
    4 Buy, 10 Hold, 3 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 23 | New: 30
Trade ACOR Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Leerink Partners resumes coverage on Acorda Therapeutics, Inc. (NASDAQ: ACOR) with a Market Perform rating and a price target of $25.00.

Analyst Paul Matteis commented, "Acorda is a biotechnology company that is approaching a set of meaningful catalysts that on balance precipitate multiple key strategic decisions for the company in 2017. We are very bullish on CVT-301 in Parkinson's Disease (PD) OFFs; however, based on outstanding formulation risk, IP uncertainty, the small clinical benefit seen in ph2 and the need for large expensive ph3's, we are considerably more cautious on the Ampyra (dalfampridine) once-daily (QD) Stroke program. Meanwhile, based on prior MEDACorp patent key opinion leader (KOL) feedback and what we see as an uphill battle in the IPR/P4 processes, we believe investors should largely assume that generics hit the Ampyra business in 2H18/2019, well ahead of 2025-2027 expiry for 4 method-of-treatment patents."

For an analyst ratings summary and ratings history on Acorda Therapeutics, Inc. click here. For more ratings news on Acorda Therapeutics, Inc. click here.

Shares of Acorda Therapeutics, Inc. closed at $20.83 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Add Your Comment